- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07662408
Comparison of Norepinehrine Versus Phenylepherine Infusion for Prevention of Post-spinal Hypotension
Comparison of Norepinephrine Versus Phenylephrine Infusion for Prevention of Hypotension Due to Subarachnoid Block in Elderly Patients Undergoing Orthopedic Hip Surgery:A Prospective Randomized Trial
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Spinal anesthesia-induced hypotension is a common and clinically significant complication in elderly patients undergoing orthopedic hip surgery. Age-related physiological changes, impaired autonomic responses, and reduced cardiovascular reserve increase susceptibility to hypotension after subarachnoid block, which may result in organ hypoperfusion, myocardial ischemia, nausea, vomiting, and increased perioperative morbidity.
Phenylephrine is traditionally used for prevention and treatment of spinal anesthesia-induced hypotension because of its potent alpha-adrenergic vasoconstrictive effect. However, its use may be associated with reflex bradycardia and reduction in cardiac output. Norepinephrine, which possesses both alpha-adrenergic and mild beta-adrenergic activity, may provide better maintenance of heart rate and cardiac output while effectively preserving blood pressure.
This prospective randomized double-blinded clinical trial will be conducted at the Department of Anesthesia, Intensive Care and Pain Management, Sohag University Hospitals, after approval from the Institutional Ethics Committee. Elderly patients aged 60 years or older, classified as ASA physical status I-III and scheduled for elective orthopedic hip surgery under spinal anesthesia, will be enrolled after obtaining written informed consent.
Studietype
Registrering (Antatt)
Fase
- Fase 4
Kontakter og plasseringer
Studiekontakt
- Navn: Ahmed Abdelhamed Faress, Resident
- Telefonnummer: 01065080913
- E-post: drahmedfaress23896@gmail.com
Studer Kontakt Backup
- Navn: Fawzy Abbas Badawy, Professor
Studiesteder
-
-
-
Sohag, Egypt
- Rekruttering
- Sohag university hospital
-
Ta kontakt med:
- Mohamed N Hamdoun, Professor
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Age 60 years or older.
- ASA physical status I-III.
- Scheduled for elective hip surgery under subarachnoid block.
- Willing to provide written informed consent.
Exclusion Criteria:
- Patient refusal.
- Contraindications to subarachnoid block.
- Severe cardiac disease.
- Uncontrolled hypertension.
- Allergy to study drugs.
- Emergency surgery.
- Monoamine oxidase inhibitor use.
- Cognitive impairment preventing informed consent.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Norepinehrine group
• NE group: norepinephrine infusion at 8 µg/min.
Infusion will continue for 45 minutes after spinal anesthesia.
|
norepinephrine infusion at 8 µg/min.
Infusion will continue for 45 minutes after spinal anesthesia.
|
|
Eksperimentell: Phenylepherine group
PhE group: phenylephrine infusion at 100 µg/min Infusion will continue for 45 minutes after spinal anesthesia.
|
phenylephrine infusion at 100 µg/min.
Infusion will continue for 45 minutes after spinal anesthesia.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean intaroperative heart rate (beats /minute) during vasopressor infusion measured by continous electrocardiogrammonitoring
Tidsramme: From the start of subarachnoid block until the end of surgery .
|
Heart rate will be continously monitored using standar electrocardiogram monitoring.
to compare the effect of norepinephrine versus phenylephrine infusion on hemodynamics.
|
From the start of subarachnoid block until the end of surgery .
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of spinal anesthesia-induced hypotension
Tidsramme: From the administration of spinal anesthesia until the end of the procedure.
|
Defined as a decrease in mean arterial pressure (MAP) to <80% of baseline measurd by non-invasive blood pressure monitoring .
|
From the administration of spinal anesthesia until the end of the procedure.
|
|
Incidence of bradycardia
Tidsramme: Throughout the intraoperative period
|
Defined as heart rate ≤ 50 beats/min.
|
Throughout the intraoperative period
|
|
Mean arterial pressure (MAP) trends measured using non-invasive blood pressure monitoring
Tidsramme: Every 5 minutes from the start of spinal anesthesia until the end of surgery.
|
Monitoring the stability of blood pressure during vasopressor infusion
|
Every 5 minutes from the start of spinal anesthesia until the end of surgery.
|
|
Incidence of reactive hypertension measured by non-invasive blood pressure monitoring
Tidsramme: From the start of vasopressor infusion until the end of surgery.
|
Defined as mean arterial pressure (MAP) > 125% of baseline.
|
From the start of vasopressor infusion until the end of surgery.
|
|
Total intraoperative intavenous fluid
Tidsramme: At the end of the surgical procedure.
|
Total volume of intravenous fluids administered in milliliters
|
At the end of the surgical procedure.
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Soh-Med-26-5-9MS
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .